The association between previous use of <scp>anti‐obesity</scp> medication and semaglutide weight loss outcomes

Ghusn, Wissam; Fansa, Sima; Anazco, Diego; Tama, Elif; Cifuentes, Lizeth; Gala, Khushboo; De La Rosa, Alan; Sacoto, Daniel; Campos, Alejandro; Feris, Fauzi; Hurtado, Daniela; Acosta, Andres

doi:10.1111/dom.15523

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences in individual specificity and tolerance to GLP-1 RAs may be the main reason for differences in weight loss ( Ruder, 2023 ), with racial differences also contributing ( Dobbie et al, 2024 ). Meanwhile, the recent observation that previous use of anti-obesity medication is associated with poorer weight loss outcomes with semaglutide further expands our knowledge that GLP-1 RAs produce poor weight loss ( Ghusn et al, 2024 ).…”

Section: Discussionmentioning

confidence: 95%

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

He,

Li,

Yang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity of real-world data on their safety and tolerability for metabolic and nutritional adverse events in large sample populations. This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).Methods: AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023. The reported odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayesian Geometric Mean and Bayesian Confidence Propagation Neural Network were employed to identify AE signals.Results: A system organ class of metabolism and nutrition disorders was employed to filter AE reports, resulting in the identification of 10,450 reports for exenatide, 2,860 reports for liraglutide, 240 reports for albiglutide, 4,847 reports for dulaglutide, 2,905 reports for semaglutide, 1,089 reports for tirzepatide, and 13 reports for lixisenatide. Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders. The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22). Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%). The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs (p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile.Conclusion: Our study suggests that exenatide, liraglutide, and semaglutide are more susceptible to metabolic and nutritional AEs than other GLP-1 RAs. Liraglutide, dulaglutide, semaglutide, and tirzepaptide’s potential to induce dehydration, necessitates special attention. Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders.

show abstract

Section: Discussionmentioning

confidence: 95%